Paul Goldberg is the editor and publisher of The Cancer Letter. He joined the publication in 1986.

His coverage has had a profound impact on the field of oncology, leading to numerous Congressional investigations, and helped change policy, regulation, and standards of care.

Paul’s reporting has been recognized by the Washington DC Professional Chapter of the Society of Professional Journalists, the Gerald Loeb Awards, the Association of Health Care Journalists, and the Newsletter and Electronic Publishers Foundation.

His articles have appeared in The New York Times, The Wall Street Journal, The Washington Post and The Washington Monthly, and he has been featured on 60 Minutes, 20/20, CNN and NPR. He is also a novelist and author of nonfiction books.

His author website is

Paul graduated from Duke University with a B.A. in economics in 1981.


Latest Stories

An award-winning investigative documentary film about power morcellation—a once-popular “minimally invasive” surgical procedure—is now available on major streaming platforms.
Karen E. Knudsen was named CEO of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network.
Conversation with The Cancer Letter
City of Hope has received a $50 million gift for a 190,000-square-foot outpatient center in Irvine, Calif.As a result of the gift, from Lennar Foundation, an offshoot of a building company, the facility, which is slated to be opened in 2022, will be named Lennar Foundation Cancer Center at City of Hope Orange County. 
Health Disparities
We are shocked and horrified by the recent spate of violence and hate crimes against people of Asian and Pacific Islander  descent across the United States.In response to these events, The Cancer Letter is stepping up coverage of inequities and disparities—and we are seeking your help and guidance on an upcoming series of investigative stories.As a publication that actively advocates for racial justice and health equity, we condemn these attacks, which have led to deaths, severe injuries, and widespread fear in AAPI communities.
José Baselga, an expert in the development of molecular targeted agents and an executive at AstraZeneca, died of Creutzfeldt-Jakob, an extremely rare, rapidly progressing, degenerative brain disorder.
In 1995, a group of doctors who advocated treating breast cancer with high dose chemotherapy with bone marrow transplantation made an attempt to include that highly toxic procedure in the guidelines of the nascent National Comprehensive Cancer Network.